Science & Innovation
Biogen R&D is driven by the potential to transform patient lives. We work in disease areas with some of the greatest unmet need. We work relentlessly, knowing that bold new possibilities await discovery. As a leading global biotechnology company, we work toward those life-changing moments that could become a historic point in our pursuit of innovative treatments.
Our deep scientific expertise, and our courage to take risks make us leaders in the research and development of medicines with the potential to transform patient lives.
Alzheimer’s Disease and Dementia
Our diverse portfolio of investigational products includes several assets targeting early-stage Alzheimer’s disease.
We are taking a variety of approaches to further our understanding of MS and how to treat it.
Our scientists continue to work toward new potential therapeutics for patients living with spinal muscular atrophy (SMA) while advancing potential therapies for amyotrophic lateral sclerosis (ALS).
With capabilities in multiple drug modalities, including small molecules, protein therapeutics, antisense oligonucleotides (ASOs) and gene therapy, Biogen pursues the most appropriate modality for each target.
Often taken orally as a pill and can readily distribute into cells and tissues.
Protein Therapeutics (Biologics)
Allow targeting of serious diseases in ways that might not be possible with other technologies.
Antisense Oligonucleotides (ASOs)
Alter RNA and either resore desired protein expression or reduce and modify toxic proteins.
Target the root causes of genetic diseases.